<DOC>
	<DOC>NCT01451398</DOC>
	<brief_summary>Insulin-naive subjects with Type 2 Diabetes Mellitus who are sub-optimally controlled on either maximum tolerated dose of metformin or maximum tolerated dose of metformin plus one or two other oral anti-diabetic medications will have either Prandial Technosphere® Insulin or Technosphere Powder (placebo) added to their oral antidiabetic drugs.</brief_summary>
	<brief_title>Comparison of Technosphere® Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>HbA1c &gt; or = to 7.5% and &lt; or = to 10.0% Body mass index (BMI) &lt; or = to 45 kg/m2 Non smoker for at least 6 months before Screening Clinical diagnosis of type 2 diabetes mellitus for more than 12 months Currently receiving as diabetes treatment only metformin or 2 or more OADs and on stable doses for at least 3 months before enrollment Subjects receiving metformin must be on at least 1.5gm daily, or up to the maximum tolerated dose Subjects treated with a sulfonylurea must be on at least 50% of the total maximum approved dose for a given agent Subjects receiving a DPP4 inhibitor must receive the maximum approved dose specific for that agent Metiglinide and alphaglucoside inhibitors must be taken at the highest tolerated dose within the approved dose range No previous or current treatment with insulin, except during an acute illness, gestational diabetes, or at time of initial diagnosis of diabetes Forced expiratory volume in one second (FEV1) &gt; or = to 70% Third National Health and Nutrition Examination Survey (NHANES III) predicted Forced vital capacity (FVC) &gt; or = to 70% NHANES III predicted Forced expiratory volume in one second as a percentage of forced vital capacity (FEV1/FVC) &gt; or = to NHANES III lower limit of normal (LLN) History of chronic obstructive pulmonary disease (COPD), clinically proven asthma, or any other clinically important pulmonary disease (eg, pulmonary fibrosis) Any clinically significant radiological findings on screening chest xray Use of medications for asthma, COPD, or any other chronic respiratory conditions Evidence of serious complications of diabetes (proliferative retinopathy, autonomic neuropathy with symptoms of gastroparesis or cardiac arrhythmia; sensory neuropathy that makes manipulation of the Gen2C inhaler difficult) Renal disease or renal dysfunction Significant cardiovascular dysfunction or history thereof within 12 months of screening; serious arrhythmia, treatment with medications to control/treat arrhythmias; myocardial infarction; cardiac surgery; history of valvular heart disease Previous or current use of amiodarone Treatment with glucagonlike peptide1 (GLP1) analogs, thiazolidinediones (TZD), or weight loss drugs (eg, sibutramine, orlistat) within 3 months of screening History of pulmonary embolism or deep venous thrombosis in the 12 months before Screening History of recent blood transfusion (within previous 3 months) or diagnosis of hemoglobinopathies that may affect HbA1c measurements</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>